Table 3. Most common AEs (≥20 % of patients overall) observed in the 15 patients during exposure to the Cidofovir and chemoradiotherapy combination (weeks 1 to 10).
| AEs | Total | Related to treatment |
|---|---|---|
| N (%*) | N (%*) | |
| Nausea / vomiting | 14 (93) | 14 (93) |
| Diarrhea | 14 (93) | 14 (93) |
| Abdominal pain | 13 (87) | 2 (13) |
| Asthenia | 12 (80) | 7 (47) |
| Anorexia | 10 (67) | 8 (53) |
| Constipation | 9 (60) | 5 (33) |
| Urinary tract infection | 7 (47) | 4 (27) |
| Headache | 7 (47) | 1 (7) |
| Vaginal bleeding | 6 (40) | 0 |
| Fever | 6 (40) | 2 (13) |
| Myalgia | 5 (33) | 1 (7) |
| Vaginal discharge | 5 (33) | 1 (7) |
| Pain in the lower limbs | 4 (27) | 1 (7) |
| Anxiety / depression | 4 (27) | 1 (7) |
| Dizziness | 3 (20) | 0 |
| Weight loss | 3 (20) | 3 (20) |
| Hematuria | 3 (20) | 1 (7) |
| Dysesthesia | 3 (20) | 1 (7) |
AEs: adverse events, N: number of patients, RT: radiotherapy.
*
% of patients who experienced the adverse event / total number of patients